Bleeding Disorders
Conference Coverage
Bleeding episodes more common in boys with VWD
SAN DIEGO – Bleeding episodes and need for treatment were more frequent among boys with types 1 and 2 von Willebrand disease.
Feature
Of ‘miracles’ and money: Why hemophilia drugs are so expensive
The U.S. hemophilia drug market, which serves about 20,000 patients, is worth $4.6 billion a year.
Feature
Hemophilia A treatment gains approval in Europe
Emicizumab is now approved in Europe and the United States for routine prophylaxis of bleeding episodes in people with factor VIII inhibitors.
Feature
States strive to curb costs for a crucial – but exorbitant – hemophilia treatment
“There aren’t a lot of options available to Medicaid programs in terms of controlling costs, because we don’t set the initial costs”
News
PK dosing software available in US
Pharmacokinetic (PK) dosing software intended for use in patients with hemophilia A is now available in the US. This free, web-based,...
News
EC approves emicizumab for hemophilia A with inhibitors
The European Commission (EC) has granted marketing authorization for emicizumab (Hemlibra®), a bispecific factor IXa- and factor X-directed...
News
Gene therapy for hemophilia A gets fast-track review
The FDA has granted breakthrough therapy designation to a gene therapy product aimed at hemophilia A.
News
Team creates device to study hemostasis
Researchers have engineered a miniature model system for studying hemostasis. They believe the device could serve as a drug discovery platform...
News
Product seems effective for ITI in severe hemophilia A
Results of a retrospective study suggest a recombinant factor VIII Fc fusion protein (rFVIIIFc) can be effective for immune tolerance induction (...
News
Product increases FIX levels in hemophilia B
MADRID—The recombinant factor IX (FIX) product CB 2679d/ISU304 can increase FIX levels in patients with severe hemophilia B, according to a phase...
News
Factor IX product launched in US
The recombinant, GlycoPEGylated coagulation factor IX product Rebinyn® is now available in the US for the treatment of patients with hemophilia B...